{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:36:44Z","timestamp":1789774604274,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.leukres.2024.107567","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:49:36Z","timestamp":1724388576000},"page":"107567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide"],"prefix":"10.1016","volume":"145","author":[{"given":"Silvia","family":"Cingelova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mikuskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"Demitrovicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Mikudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alica","family":"Slobodova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Spanikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Vasickova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubos","family":"Drgona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iveta","family":"Oravcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2024.107567_bib1","first-page":"1007","article-title":"Differentiation syndrome induced by arsenic trioxide when receiving the therapy of all-trans retinoic acid\/arsenic trioxide combination: a case report and review of literature","volume":"1","author":"Zhu","year":"2018","journal-title":"Ann. Blood Cancer"},{"issue":"19","key":"10.1016\/j.leukres.2024.107567_bib2","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2024.107567_bib3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2024.107567_bib4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41375-019-0589-3","article-title":"Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial","volume":"34","author":"Cicconi","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2024.107567_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2024.107567_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2024.107567_bib7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107567_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The\" retinoic acid syndrome\" in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.leukres.2024.107567_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.10156","article-title":"ATRA syndrome with extensive organ infiltration","volume":"71","author":"Kakkar","year":"2002","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2024.107567_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12185-014-1603-1","article-title":"Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction","volume":"100","author":"Li","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"03","key":"10.1016\/j.leukres.2024.107567_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4103\/ijmpo.ijmpo_36_16","article-title":"Pancreatitis in acute promyelocytic leukemia: drug-induced or differentiation syndrome?","volume":"38","author":"De","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.leukres.2024.107567_bib12","first-page":"1","article-title":"Clinical indicators of hepatotoxicity in newly diagnosed acute promyelocytic leukemia patients undergoing arsenic trioxide treatment","author":"Zhang","year":"2003","journal-title":"Biol. Trace Elem. Res."},{"issue":"21","key":"10.1016\/j.leukres.2024.107567_bib13","first-page":"1805","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"135","author":"Sanz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107567_bib14","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the PETHEMA group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"13","key":"10.1016\/j.leukres.2024.107567_bib15","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","article-title":"All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol","volume":"100","author":"Tallman","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107567_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mco.2021.2274","article-title":"Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk","volume":"14","author":"Wen","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107567_bib17","first-page":"838","article-title":"Progressive hyperleukocytosis associates with differential syndrome in acute promyelocytic leukemia patients treated with all-trans retinoic acid and arsenic trioxide","volume":"4","author":"Li","year":"2020","journal-title":"HemaSphere"},{"issue":"11","key":"10.1016\/j.leukres.2024.107567_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood.V112.11.138.138","article-title":"Risk-adapted treatment of acute promyelocytic leukemia: results of the PETHEMA LPA2005 trial using all-trans retinoic acid and anthracycline with cytarabine for high-risk patients","volume":"112","author":"Sanz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107567_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-022-10499-2","article-title":"Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia","volume":"23","author":"Wen","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2024.107567_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107567_bib21","first-page":"475","article-title":"Chinese Society of Hematology, Chinese Medical Association & Chinese Society of Hematologist, Chinese Medical Doctor Association. [Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2014)]","volume":"35","author":"Jun","year":"2014","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2024.107567_bib22","first-page":"95","article-title":"Leukocyt\u00f3za a diferencia\u010dn\u00ed syndrom p\u0159i l\u00e9\u010db\u011b akutn\u00ed promyelocyt\u00e1rn\u00ed leukemie pomoc\u00ed oxidu arsenit\u00e9ho","volume":"17","author":"Koristek","year":"2020","journal-title":"Acta Med."},{"issue":"4","key":"10.1016\/j.leukres.2024.107567_bib23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2141.2000.01936.x","article-title":"Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia","volume":"108","author":"Di Bona","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107567_bib24","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2012-08-449918","article-title":"Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL","volume":"121","author":"Rego","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2024.107567_bib25","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","article-title":"Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy","volume":"27","author":"Grimwade","year":"2009","journal-title":"J. Clin. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T12:52:56Z","timestamp":1726231976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":25,"alternative-id":["S0145212624001334"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107567","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107567","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107567"}}